Tecan Group AG

LSE:0QLN Stock Report

Market Cap: CHF 2.7b

Tecan Group Valuation

Is 0QLN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QLN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0QLN (CHF210.2) is trading below our estimate of fair value (CHF236.04)

Significantly Below Fair Value: 0QLN is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QLN?

Key metric: As 0QLN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QLN. This is calculated by dividing 0QLN's market cap by their current earnings.
What is 0QLN's PE Ratio?
PE Ratio26.6x
EarningsCHF 101.34m
Market CapCHF 2.70b

Price to Earnings Ratio vs Peers

How does 0QLN's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QLN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average54.2x
ERGO Ergomed
46.7x14.2%UK£701.1m
HVO hVIVO
8.5x-15.2%UK£148.0m
HIK Hikma Pharmaceuticals
19x12.7%UK£4.3b
GNS Genus
142.7x37.7%UK£1.1b
0QLN Tecan Group
26.6x14.9%CHF 2.7b

Price-To-Earnings vs Peers: 0QLN is good value based on its Price-To-Earnings Ratio (26.6x) compared to the peer average (56.7x).

Price to Earnings Ratio vs Industry

How does 0QLN's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0QLN 26.6xIndustry Avg. 36.8xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0QLN is good value based on its Price-To-Earnings Ratio (26.6x) compared to the European Life Sciences industry average (36.8x).

Price to Earnings Ratio vs Fair Ratio

What is 0QLN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QLN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26.6x
Fair PE Ratio23.9x

Price-To-Earnings vs Fair Ratio: 0QLN is expensive based on its Price-To-Earnings Ratio (26.6x) compared to the estimated Fair Price-To-Earnings Ratio (23.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QLN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 210.20
CHF 286.14
+36.1%
15.6%CHF 384.00CHF 241.00n/a7
Nov ’25CHF 220.20
CHF 295.29
+34.1%
15.5%CHF 384.00CHF 241.00n/a7
Oct ’25CHF 276.00
CHF 348.75
+26.4%
11.0%CHF 415.00CHF 300.00n/a8
Sep ’25CHF 284.40
CHF 351.71
+23.7%
11.4%CHF 415.00CHF 300.00n/a7
Aug ’25CHF 327.20
CHF 385.71
+17.9%
8.2%CHF 415.00CHF 330.00n/a7
Jul ’25CHF 302.20
CHF 396.57
+31.2%
5.8%CHF 418.00CHF 347.00n/a7
Jun ’25CHF 319.00
CHF 397.71
+24.7%
6.0%CHF 420.00CHF 347.00n/a7
May ’25CHF 327.00
CHF 395.57
+21.0%
7.2%CHF 420.00CHF 332.00n/a7
Apr ’25CHF 373.86
CHF 397.14
+6.2%
7.1%CHF 420.00CHF 332.00n/a7
Mar ’25CHF 342.84
CHF 390.86
+14.0%
10.5%CHF 450.00CHF 311.00n/a7
Feb ’25CHF 330.66
CHF 392.29
+18.6%
10.6%CHF 450.00CHF 311.00n/a7
Jan ’25CHF 345.13
CHF 412.50
+19.5%
14.8%CHF 480.00CHF 300.00n/a6
Dec ’24CHF 309.59
CHF 435.00
+40.5%
8.7%CHF 480.00CHF 372.00n/a5
Nov ’24CHF 265.80
CHF 447.40
+68.3%
4.9%CHF 480.00CHF 417.00CHF 220.205
Oct ’24CHF 314.83
CHF 447.83
+42.2%
4.4%CHF 480.00CHF 417.00CHF 276.006
Sep ’24CHF 354.85
CHF 448.86
+26.5%
4.1%CHF 480.00CHF 417.00CHF 284.407
Aug ’24CHF 347.33
CHF 466.86
+34.4%
2.8%CHF 485.00CHF 450.00CHF 327.207
Jul ’24CHF 343.20
CHF 463.83
+35.1%
2.6%CHF 480.00CHF 450.00CHF 302.206
Jun ’24CHF 354.40
CHF 464.83
+31.2%
2.4%CHF 480.00CHF 450.00CHF 319.006
May ’24CHF 387.85
CHF 461.80
+19.1%
2.2%CHF 480.00CHF 450.00CHF 327.005
Apr ’24CHF 399.42
CHF 460.33
+15.3%
4.3%CHF 485.00CHF 425.00CHF 373.866
Mar ’24CHF 378.20
CHF 459.00
+21.4%
5.0%CHF 483.00CHF 425.00CHF 342.845
Feb ’24CHF 382.04
CHF 470.00
+23.0%
4.2%CHF 493.00CHF 440.00CHF 330.664
Jan ’24CHF 424.24
CHF 470.00
+10.8%
4.2%CHF 493.00CHF 440.00CHF 345.134
Dec ’23CHF 399.64
CHF 467.50
+17.0%
3.6%CHF 483.00CHF 440.00CHF 309.594
Nov ’23CHF 356.60
CHF 467.50
+31.1%
3.6%CHF 483.00CHF 440.00CHF 265.804

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$81.2b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$742.70

7D

-0.8%

1Y

-8.6%

hVIVO

UK£146.3m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-1.1%

1Y

6.4%

Hikma Pharmaceuticals

UK£4.3b

Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.

HIKL

UK£19.41

7D

4.0%

1Y

12.9%